| Ytd | -96.41% | |
| 1y | -95.32% |
| Open | 9.59 | Prev Close | 9.76 | Low | 8.77 | High | 9.64 | Mkt Cap | 54.47M |
| Vol | 361.19K | Avg Vol | 376.08K | EPS | -52.80 | P/E | N/A | Forward P/E | -0.69 |
| Beta | 2.00 | Short Ratio | 3.80 | Inst. Own | 77.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 12.26 | 200-d Avg | 54.95 | 1yr Est | 132.48 |
GOSS News
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a
Corient Private Wealth LP increased its position in shares of Gossamer Bio, Inc. (NASDAQ: GOSS) by 4
Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market
– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyse
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a B
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-mark
Hsbc Holdings PLC boosted its holdings in Gossamer Bio, Inc. (NASDAQ: GOSS) by 1,289.4% during the u
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmac
Gossamer Bio, Inc. (Nasdaq: GOSS) (the âCompanyâ or âGossamerâ), a clinical-stage biopharmac
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage bio
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the develop
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmac
Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutini
Gossamer Bio, Inc. (Nasdaq: GOSS) (the âCompanyâ or âGossamerâ), a clinical-stage biopharmac
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Addition
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and l
Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Esti
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst con
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings pag
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also receive
Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Gossamer Bio Inc. (NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to sub
Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a
Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Cap
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's
Special Meeting: Approval of Proposals Related to Convertible Note Exchange and Reverse Stock SplitA
– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutin
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a B
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the